Daniel Martinez-Ramirez
Clinical and Research Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Parkinson’s disease (PD) is the second most common neurodegenerative disorder worldwide and is characterized by progressive motor and non-motor manifestations. Its rising prevalence poses significant challenges for clinical management and public health. Type 2 diabetes mellitus (T2DM), the most frequent metabolic disorder, shares several pathogenic mechanisms with PD, including mitochondrial dysfunction, insulin resistance, and oxidative stress. Epidemiological studies suggest a higher incidence of PD among individuals with T2DM, with growing evidence that diabetes may accelerate the onset and progression of motor and cognitive symptoms. This narrative review summarizes current knowledge on the relationship between T2DM and PD, with emphasis on epidemiological associations, shared biological pathways, and the therapeutic implications of antidiabetic agents. Available data indicate that patients with both PD and T2DM tend to experience a faster progression of motor and cognitive decline. Clinical trials assessing hypoglycemic agents have reported heterogeneous findings: pioglitazone failed to demonstrate neuroprotective effects, while exenatide showed temporary improvements in motor function that were not sustained after treatment discontinuation. Experimental studies also suggest possible neuroprotective actions of metformin and dipeptidyl peptidase 4 inhibitors, although well-designed clinical trials are still lacking. The interaction between T2DM and PD highlights the importance of metabolic factors in neurodegeneration. Further studies are required to determine the impact of diabetes and its treatments on the PD course and to explore antidiabetic drugs as potential disease-modifying therapies.
Year:
2025
Introduction: While there is a growing body of evidence indicating a potential connection between Parkinson’s disease and diabetes mellitus, there is a lack of focus on investigating how diabetes correlates with the severity of both motor and non-motor symptoms in Parkinson’s disease. Objective: This study examined and contrasted both motor and non-motor symptoms in patients diagnosed with Parkinson’s disease, stratified by the presence or absence of diabetes. Methods: A total of 40 Parkinson’s disease patients, divided into two groups (with and without diabetes), were assessed using various scales, including the Movement Disorders Society – Unified Parkinson’s Disease Rating Scale, Scales for Outcomes in Parkinson’s Disease - Autonomic Dysfunction and Non-Motor Symptoms, Beck Depression Inventory, Montreal Cognitive Assessment, and Parkinson’s Disease Questionnaire-39. Demographic and clinical characteristics were also recorded. Statistical analyses included t-tests, Mann-Whitney U tests, and Fisher’s exact test. Results: Significant differences were observed in the motor sub-score of postural instability and gait disturbance symptoms, autonomic total scores, urinary function domain, depression scores, and quality of life in the mobility and emotional domains between the Parkinson’s disease non-diabetes, and Parkinson’s disease - diabetes groups. Conclusions: Our study unveiled differences in motor and Non-Motor Symptoms among patients with Parkinson’s disease and diabetes, underscoring the influence of diabetes on manifestations of the disease.
Year:
2025
Background Although levodopa remains the gold standard treatment for Parkinson’s disease (PD), its chronic use is associated with levodopa-induced dyskinesia (LID), a motor complication that impacts prognosis, quality of life, and treatment costs. Most known LID-associated factors have been identified in European-descendant populations. Objectives To describe the epidemiology of LID in Latin American and Caribbean (LATAM) countries and assess the relevance of known and novel LID-associated factors in this population. Methods We conducted a cross-sectional study using data from the Latin American Research consortium on the Genetics of Parkinson’s Disease (LARGE-PD). We included PD patients with information on LID status and levodopa use from eight LATAM countries. LID prevalence was calculated overall and by country. Countries were compared on demographic and clinical variables. Logistic regression was used to identify associations with LID. Results A total of 3,695 PD patients (58.8% male) were included. Overall LID prevalence was 25.4% [95% CI: 24.06–26.87], ranging from 9.3% in Colombia to 45.1% in Puerto Rico. Prevalence increased progressively with longer disease duration. Country comparisons showed that not all known LID-associated factors explained prevalence differences. In logistic regression, fast disease progression was significantly associated with LID (OR: 1.55, 95%CI: 1.16–2.07), while sex was not (OR: 1.02, 95%CI: 0.87–1.18). Conclusions This is the largest study on LID epidemiology in LATAM. While some known risk factors remain relevant, others, like sex, do not, underscoring the need for population-specific studies. Future work should integrate environmental, clinical, and genetic data to better understand LID mechanisms.
Year:
2025
Collaborators (4)
Henry Mauricio Chaparro-Solano
Director de Investigaciones
Universidad Autónoma de Bucaramanga
Thiago Peixoto Leal
Senior Scientist
Morehouse School of Medicine
Sarael Alcauter
Associate Professor
National Autonomous University of Mexico
Ignacio Fernandez Mata
Associate Staff
Cleveland Clinic
Make your next move.
Prepare your application
Review drafts before you send them.